## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($212.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Jump Financial LLC Buys New Shares in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251208T114452 | Bullish | Relevance: 100%
-  Jump Financial LLC has acquired a new stake in AbbVie Inc. (NYSE:ABBV) by purchasing 84,789 shares valued at approximately $15,739,000 during the second quarter. Other institutional investors also increased their holdings in AbbVie, which reported strong quarterly earnings and increased its dividend. The company also received several positive analyst ratings and price target increases.

**2. The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.**
- Source: The Globe and Mail | 20251207T041139 | Bullish | Relevance: 100%
-  The pharmaceutical sector is experiencing a surge, with the iShares U.S. Pharmaceuticals ETF up almost 29% year to date. AbbVie (NYSE: ABBV) is highlighted as a stock to watch, having exceeded Wall Street's expectations with its third-quarter results. The company's top drugs, Skyrizi, Rinvoq, and Humira, have shown significant sales growth, and management projects continued strong performance for Rinvoq and Skyrizi.

**3. California Public Employees Retirement System Sells 778,732 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251207T090752 | Somewhat-Bullish | Relevance: 99%
- The California Public Employees Retirement System (CalPERS) significantly reduced its stake in AbbVie Inc. (NYSE:ABBV) by 13.7%, selling 778,732 shares in Q2 and now holding 4,890,752 shares valued at approximately $907.8 million. This makes AbbVie its 24th largest position, accounting for 0.28% of the fund's holdings. The article also highlights AbbVie's strong Q3 earnings beat, increased quarterly dividend, and a consensus "Moderate Buy" rating from analysts.

**4. Ose Immunotherapeutics stock falls after AbbVie deal amendment By Investing.com**
- Source: Investing.com UK | 20251208T131948 | Neutral | Relevance: 99%
- Ose Immunotherapeutics' stock dropped 4.25% after amending its agreement with AbbVie, shifting more financial and developmental responsibility to Ose. Under the revised terms, Ose will now fund and conduct the Phase 1 study for their immunotherapy partnership, eliminating a previously anticipated milestone payment. While the overall deal value remains unchanged at $700 million, the market reacted negatively to Ose's increased financial burden and the removal of near-term payment certainty.

**5. Federated Hermes Inc. Acquires 134,942 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251207T120752 | Bullish | Relevance: 99%
- Federated Hermes Inc. increased its holdings in AbbVie Inc. by 4.1% during the second quarter, purchasing an additional 134,942 shares and bringing its total stake to 3,418,332 shares valued at approximately $634.5 million. This makes AbbVie the fund's sixth-largest holding, representing about 1.2% of its portfolio. AbbVie recently reported strong earnings, exceeding analyst estimates with $1.86 EPS and $15.78 billion in revenue, and subsequently raised its quarterly dividend to $1.73 per share, resulting in an annual yield of roughly 3.1%.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $394.1B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.7 |
| Current P/E | 21.0 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 5.4pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.89), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.44% (CS: 32) | Weak |
| RSI_14 | 44.1 | Neutral |
| MACD Histogram | -0.89 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 0.977x | Below |
| vs SMA200 | 1.089x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $222.99
- **Stop Loss:** $212.71 (4.6% risk)
- **Target:** $233.27 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $6,466.71
- **Portfolio %:** 6.47%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*